Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIALIZE: Sodium Zirconium Cyclosilicate for Hyperkalemia in Hemodialysis
NCT03303521Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2017
- Primary completion
- Nov 2018
- Modality
- DNA Intercalators/Alkylators
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in hyperkalemia comparing Sodium Zirconium Cyclosilicate with Placebo (2 arms). Primary endpoint: Percentage of Responders at 8 weeks. Started Dec 2017; status: completed.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on NCT03303521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03303521.